[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602984":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":45,"centralContacts":50,"locations":55,"responsibleParty":72,"collaborators":11,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":11,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":11,"enrollmentInfo":83,"targetDuration":11,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":11,"overallStatus":95,"whyStopped":11,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Changchun GeneScience Pharmaceutical Co., Ltd.","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Low dose of Megestrol Acetate Oral Suspension","EXPERIMENTAL",null,[13],"Drug: Low dose of Megestrol Acetate Oral Suspension combined with standard therapy",{"label":15,"type":10,"description":11,"interventionNames":16},"Medium dose of Megestrol Acetate Oral Suspension",[17],"Drug: Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy",{"label":19,"type":10,"description":11,"interventionNames":20},"High dose of Megestrol Acetate Oral Suspension",[21],"Drug: High dose of Megestrol Acetate Oral Suspension combined with standard therapy",{"label":23,"type":24,"description":11,"interventionNames":25},"Megestrol Acetate Oral Suspension Placebo","ACTIVE_COMPARATOR",[26],"Drug: Megestrol Acetate Oral Suspension Placebo combined with standard therapy",[28,33,37,41],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","Low dose of Megestrol Acetate Oral Suspension combined with standard therapy","A single dose of 312.5 mg\u002Fday, administered once daily (QD) for 7 consecutive days.",[9],{"type":29,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy","A single dose of 625 mg\u002Fday, administered once daily (QD) for 7 consecutive days.",[15],{"type":29,"name":38,"description":39,"armGroupLabels":40,"otherNames":11},"High dose of Megestrol Acetate Oral Suspension combined with standard therapy","A single dose of 937.5 mg\u002Fday, administered once daily (QD) for 7 consecutive days.",[19],{"type":29,"name":42,"description":43,"armGroupLabels":44,"otherNames":11},"Megestrol Acetate Oral Suspension Placebo combined with standard therapy","A single dose of 5 mL\u002Fday, administered once daily (QD) for 7 consecutive days.",[23],[46],{"name":47,"affiliation":48,"role":49},"Li Zhang, PHD","Sun Yat-Sen University Cancer Center","PRINCIPAL_INVESTIGATOR",[51],{"name":47,"role":52,"phone":53,"phoneExt":11,"email":54},"CONTACT","+86 20-87343458","zhangli@sysucc.org.cn",[56],{"facility":57,"status":11,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Sun Yat-sen University Cancer Center","Guangzhou","Guangdong","510000","China","CN",{"type":64,"coordinates":65},"Point",[66,67],113.25,23.11667,{"lat":67,"lon":66},[70],{"name":71,"role":52,"phone":53,"phoneExt":11,"email":54},"Li Zhang",{"type":73,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100602984","phase-1-evaluation-of-the-efficacy-and-safety-of-megestrol-acetate-in-preventing-nausea-and-vomiting-induced-by-highly-emetogenic-chemotherapy-100602984",false,"NCT07130617","Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy","A Phase Ib, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Clinical Study Evaluating the Efficacy and Safety of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of sex\n2. Histologically or cytologically confirmed lung cancer\n3. Expected survival ≥ 3 months\n4. Female subjects of childbearing potential must have negative serum pregnancy test within 72 hours prior to randomization and must be non-lactating\n5. Capable of comprehending and willingly providing signed informed consent form (ICF), and adhering to study requirements\u002Frestrictions Exclusion Criteria\n\n1\\. Received or scheduled to receive concurrent radiotherapy within 7 days prior to enrollment through Day 1-8 of treatment 2. Systemic corticosteroid therapy or sedating antihistamines within 7 days prior to enrollment 3. Poorly controlled serous cavity effusions (pleural\u002Fperitoneal\u002Fpericardial) 4. Severe cardiovascular diseases within 3 months prior to enrollment 5. Participation in other clinical trials within 30 days prior to enrollment","ALL","18 Years",{"count":84,"type":85},132,"ESTIMATED","INTERVENTIONAL",[88],"PHASE1","To evaluate the efficacy of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy in Malignant Solid Tumor Patients",[91,92,93,94],"Efficacy","Safety","Megestrol Acetate","Adult Subject","NOT_YET_RECRUITING","2025-08-12",{"date":98,"type":99},"2025-08-19","ACTUAL",{"date":101,"type":85},"2025-09-29",{"date":103,"type":85},"2026-07-31",{"name":5,"class":6},1]